These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 11933222

  • 1. Therapeutic levels of human factor VIII in mice implanted with encapsulated cells: potential for gene therapy of haemophilia A.
    García-Martín C, Chuah MK, Van Damme A, Robinson KE, Vanzieleghem B, Saint-Remy JM, Gallardo D, Ofosu FA, Vandendriessche T, Hortelano G.
    J Gene Med; 2002; 4(2):215-23. PubMed ID: 11933222
    [Abstract] [Full Text] [Related]

  • 2. Sustained and therapeutic levels of human factor IX in hemophilia B mice implanted with microcapsules: key role of encapsulated cells.
    Wen J, Vargas AG, Ofosu FA, Hortelano G.
    J Gene Med; 2006 Mar; 8(3):362-9. PubMed ID: 16311997
    [Abstract] [Full Text] [Related]

  • 3. Bone marrow mesenchymal cells for haemophilia A gene therapy using retroviral vectors with modified long-terminal repeats.
    Van Damme A, Chuah MK, Dell'accio F, De Bari C, Luyten F, Collen D, VandenDriessche T.
    Haemophilia; 2003 Jan; 9(1):94-103. PubMed ID: 12558785
    [Abstract] [Full Text] [Related]

  • 4. Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors.
    Matsui H, Shibata M, Brown B, Labelle A, Hegadorn C, Andrews C, Hebbel RP, Galipeau J, Hough C, Lillicrap D.
    Stem Cells; 2007 Oct; 25(10):2660-9. PubMed ID: 17615271
    [Abstract] [Full Text] [Related]

  • 5. Novel factor VIII variants with a modified furin cleavage site improve the efficacy of gene therapy for hemophilia A.
    Nguyen GN, George LA, Siner JI, Davidson RJ, Zander CB, Zheng XL, Arruda VR, Camire RM, Sabatino DE.
    J Thromb Haemost; 2017 Jan; 15(1):110-121. PubMed ID: 27749002
    [Abstract] [Full Text] [Related]

  • 6. Encapsulated human primary myoblasts deliver functional hFIX in hemophilic mice.
    Wen J, Xu N, Li A, Bourgeois J, Ofosu FA, Hortelano G.
    J Gene Med; 2007 Nov; 9(11):1002-10. PubMed ID: 17868187
    [Abstract] [Full Text] [Related]

  • 7. Sustained expression of human factor VIII in mice using a parvovirus-based vector.
    Chao H, Mao L, Bruce AT, Walsh CE.
    Blood; 2000 Mar 01; 95(5):1594-9. PubMed ID: 10688813
    [Abstract] [Full Text] [Related]

  • 8. Recombinant factor VIII expression in hematopoietic cells following lentiviral transduction.
    Tiede A, Eder M, von Depka M, Battmer K, Luther S, Kiem HP, Ganser A, Scherr M.
    Gene Ther; 2003 Oct 01; 10(22):1917-25. PubMed ID: 14502221
    [Abstract] [Full Text] [Related]

  • 9. Gene therapy for hemophilia A: production of therapeutic levels of human factor VIII in vivo in mice.
    Dwarki VJ, Belloni P, Nijjar T, Smith J, Couto L, Rabier M, Clift S, Berns A, Cohen LK.
    Proc Natl Acad Sci U S A; 1995 Feb 14; 92(4):1023-7. PubMed ID: 7862626
    [Abstract] [Full Text] [Related]

  • 10. [Genetic therapy for hemophiliacs--therapeutic potential and technological limits].
    Michou AI, Christ M, Pavirani A, Mehtali M.
    Transfus Clin Biol; 1997 Feb 14; 4(3):251-61. PubMed ID: 9264782
    [Abstract] [Full Text] [Related]

  • 11. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors.
    Chuah MK, Schiedner G, Thorrez L, Brown B, Johnston M, Gillijns V, Hertel S, Van Rooijen N, Lillicrap D, Collen D, VandenDriessche T, Kochanek S.
    Blood; 2003 Mar 01; 101(5):1734-43. PubMed ID: 12406898
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Characterization of Adeno-Associated Viral Vector-Mediated Human Factor VIII Gene Therapy in Hemophilia A Mice.
    Greig JA, Wang Q, Reicherter AL, Chen SJ, Hanlon AL, Tipper CH, Clark KR, Wadsworth S, Wang L, Wilson JM.
    Hum Gene Ther; 2017 May 01; 28(5):392-402. PubMed ID: 28056565
    [Abstract] [Full Text] [Related]

  • 16. Omental implantation of BOECs in hemophilia dogs results in circulating FVIII antigen and a complex immune response.
    Ozelo MC, Vidal B, Brown C, Notley C, Hegadorn C, Webster S, Harpell L, Ahlin J, Winterborn A, Handforth J, Arruda VR, Hough C, Lillicrap D.
    Blood; 2014 Jun 26; 123(26):4045-53. PubMed ID: 24829206
    [Abstract] [Full Text] [Related]

  • 17. Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains.
    Rawle FE, Shi CX, Brown B, McKinven A, Tinlin S, Graham FL, Hough C, Lillicrap D.
    J Gene Med; 2004 Dec 26; 6(12):1358-68. PubMed ID: 15493040
    [Abstract] [Full Text] [Related]

  • 18. In vivo evaluation of an adenoviral vector encoding canine factor VIII: high-level, sustained expression in hemophiliac mice.
    Gallo-Penn AM, Shirley PS, Andrews JL, Kayda DB, Pinkstaff AM, Kaloss M, Tinlin S, Cameron C, Notley C, Hough C, Lillicrap D, Kaleko M, Connelly S.
    Hum Gene Ther; 1999 Jul 20; 10(11):1791-802. PubMed ID: 10446919
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant.
    McIntosh J, Lenting PJ, Rosales C, Lee D, Rabbanian S, Raj D, Patel N, Tuddenham EG, Christophe OD, McVey JH, Waddington S, Nienhuis AW, Gray JT, Fagone P, Mingozzi F, Zhou SZ, High KA, Cancio M, Ng CY, Zhou J, Morton CL, Davidoff AM, Nathwani AC.
    Blood; 2013 Apr 25; 121(17):3335-44. PubMed ID: 23426947
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.